Ozurdex Implant
Product Images NDC 0023-3348

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ozurdex (NDC 0023-3348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ozurdex 01

A line graph comparing mean intraocular pressure (mm Hg) over various months and visits between two groups: DEX 700 (N=384) and Sham (N=326). The x-axis shows the cycle months and visits, while the y-axis represents mean intraocular pressure values ranging from 0 to 25 mm Hg.*

FDA Label Image

Ozurdex 02

Chemical structure of dexamethasone, the active ingredient in OZURDEX implant. The diagram shows the steroid backbone with labeled functional groups, hydroxyls, methyl groups, and fluorine atom.*

FDA Label Image

Ozurdex 03

Four line graphs showing the proportion of subjects gaining 15 or more letters in visual acuity over time by study visit month, comparing Ozurdex and sham groups. The graphs separate results for phakic and pseudophakic subjects from two different studies, illustrating changes across monthly study visits up to 36 months.*

FDA Label Image

Ozurdex 04

Four line graphs showing mean change from baseline in BCVA (Letter) over time in months for two studies comparing Ozurdex (dexamethasone intravitreal implant) versus sham treatment. The top two graphs represent Study 1 with phakic and pseudophakic subjects, and the bottom two graphs represent Study 2 with phakic and pseudophakic subjects. Each graph plots mean changes for Ozurdex and sham groups across multiple study visits up to 39 months.*

FDA Label Image

Ozurdex 05

FDA Label Image

Ozurdex 06

Packaging label for OZURDEX (dexamethasone) intravitreal implant 0.7 mg by Allergan, Inc., NDC 0023-3348-07. The implant is provided as one sterile, single-use applicator. The label highlights storage conditions and intravitreal injection use with Rx only designation, and includes step-by-step directions for use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.